SPRY
SPRY
NASDAQ · Biotechnology

Ars Pharmaceuticals Inc

$2.79
+0.14 (+5.28%)
As of Nov 7, 1:54 AM ET ·
Financial Highlights (FY 2026)
Revenue
85.03M
Net Income
-172,829,526
Gross Margin
76.7%
Profit Margin
-203.3%
Rev Growth
+299.7%
D/E Ratio
0.84
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 76.7% 61.2% 61.2% 61.2%
Operating Margin -212.9% 12.9% 15.2% 14.7%
Profit Margin -203.3% 9.9% 12.8% 10.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 85.03M 357.40M 350.63M 398.05M
Gross Profit 65.23M 218.64M 214.50M 243.51M
Operating Income -181,040,495 46.04M 53.12M 58.40M
Net Income -172,829,526 35.24M 44.72M 41.86M
Gross Margin 76.7% 61.2% 61.2% 61.2%
Operating Margin -212.9% 12.9% 15.2% 14.7%
Profit Margin -203.3% 9.9% 12.8% 10.5%
Rev Growth +299.7% +16.3% -1.3% +6.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 63.48M 228.52M 266.70M 231.00M
Total Equity 75.25M 545.19M 556.64M 584.56M
D/E Ratio 0.84 0.42 0.48 0.40
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -180,248,298 65.64M 71.27M 76.87M
Free Cash Flow — 46.75M 30.69M 51.61M